To examine the effect of a GLP-2 infusion on appetite sensations and ad libitum energy intake in healthy, normal weight humans. DESIGN: The experiment was performed in a randomised, blinded, and placebo-controlled crossover design. Placebo or GLP-2 was infused (infusion rate of 25 pmol/kg body wth) for 4.5 h. SUBJECTS: A total of 18 healthy, normal weight young subjects participated; eight women and 10 men. MEASUREMENTS: During the infusion, subjects recorded their appetite sensations every 30 min using visual analogue scales, and blood was sampled frequently. After 2 h of infusion, an ad libitum meal, consisting of sandwiches, was served. RESULTS: The concentration of GLP-2 was significantly higher during the GLP-2 infusion compared with placebo (Po0.0001) and increased further in both conditions in response to the meal. Neither appetite sensations, nor palatability of the test meals, or energy intake were different on the two occasions. Glucose, GLP-1, insulin, and GIP responses were also unaffected by the infusion, whereas glucagon levels were higher during the GLP-2 treatment (Po0.05). CONCLUSION: Circulating GLP-2 in physiological concentrations does not seem to play a significant role in human appetite regulation.
Introduction
In 1983, Bell et al 1, 2 discovered that the glucagon gene codes for a precursor, proglucagon, which besides glucagon contains two additional homologous peptides, glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2). Since then, efforts have been made to discover the physiological role of GLP-1 and GLP-2. GLP-2 exerts trophic effects on the small and large bowel epithelium by stimulating cell proliferation and inhibiting apoptosis; [3] [4] [5] furthermore, GLP-2 upregulates intestinal glucose transport activity. 6, 7 A possible role for peripheral GLP-2 in regulating appetite was proposed after experiments had shown that peripherally infused GLP-1 is a potent regulator of appetite and energy intake. [8] [9] [10] The reasoning was that GLP-1 and GLP-2 are products of the same gene and the same precursor and that GLP-2 is released from the intestinal L-cells in parallel with GLP-1 following nutrient ingestion. [11] [12] [13] [14] In addition, the GLP-2 receptor is expressed in a highly restricted area of the hypothalamus, namely the ventromedial nucleus, and ICV administration of GLP-2 has been shown to cause inhibition of food intake in rats. 15 Moreover, the receptor is expressed in the intestinal epithelium, 16 and GLP-2 has been shown to inhibit vagally stimulated gastric motility in pigs 17 and vagally induced acid secretion in humans. 18 These results have led to the hypothesis that GLP-2 has a supportive role in the ileal brake mechanism. In this study we investigate the possible role of peripheral GLP-2 on appetite sensations and energy intake in humans.
Materials and methods

Subjects and design
In all, 18 healthy young adults, 10 males and eight females, nonsmokers, not elite-athletes, with no history of diabetes, participated in the study (Table 1) . The women were not using oral contraceptives. The subjects were tested on two different occasions in a randomised, placebo-controlled, double-blinded crossover study. The two test days were separated by at least 3 weeks. To ensure that the women were at the same stage in their menstrual cycle, the two test days were placed within the sixth and 12th day of the menstrual cycle counting from the first day of menstruation. All subjects gave written consent after the experimental protocol had been read and explained to them. The Municipal Ethical Committee of Copenhagen and Frederiksberg approved the study.
Experimental protocol
Before each test day, the subjects followed a weight maintaining standardised diet (37 energy per cent (E%) fat, 13 E% protein, 50 E% carbohydrates, 2.0 g/MJ fibre) estimated to meet their individual energy requirement, 19, 20 adjusted to the nearest 0.5 MJ. The subjects were instructed to abstain from drinking alcohol or doing strenuous physical activities for 2 days prior to the test days to ensure equally filled glycogen stores. 21 On the test day, the subjects arrived at the department at 08.15 h after having fasted at least 12 h. They had been instructed to use the least strenuous means of transportation. The subjects drank 100 ml of water and after voiding and weighing, body composition was assessed by electrical impedance. 22 The subjects then rested in the supine position with a slight elevation of the head, and venflon catheters were inserted in both arms in the cubital vein. After 15 min of rest, a fasting blood sample was taken. At 09.30 h, infusion of test solution was started and continued for the rest of the experiment. Appetite ratings were made on 10 cm visual analogue scales (VAS) with text expressing the most positive and most negative rating anchored at each end. VAS was used to assess hunger, satiety, fullness, prospective food consumption, desires for special foods, and palatability of the test meal (taste, smell, visual appeal, aftertaste, and overall palatability). 23 Appetite sensations were recorded every half-hour and palatability ratings were assessed immediately after consumption of the test meal. Blood samples were taken at 30, 60, 90, 120, 135, 150, 165, 180, 210, 240 and 270 min after the start of infusion. After 120 min of infusion, at 11.30 h, the test meal was served and the subjects were instructed to eat ad libitum until comfortably satisfied (Figure 1 ). The time spent on eating was recorded and the amount of food eaten was measured by weighing. During the experiment, the subjects were allowed to listen to the radio or watch television or video.
Test meal
The test meal consisted of sandwiches with ham or cheese made with a homogeneous energy distribution. The distribution of energy was 37 E% fat, 13 E% protein, and 50 E% carbohydrates. To make it difficult for the subjects to compare the number of sandwiches they ate on the two test days, the sandwiches were cut in different sizes. The subjects were allowed to drink up to 400 ml water ad libitum on the first test day and the same amount of water was served on the second test day.
Infusion
For the GLP-2 infusion, human GLP-2, synthesised at Polypeptides, Wolfenbüttel, Germany, corresponding to human proglucagon 126-158, was used. The structure was confirmed by mass and sequence analysis, and the purity (498%) was assessed by HPLC. The peptide was subjected to sterile filtration, and tested for pyrogens and viruses and kept at À201C until use. On the test day, the peptide was dissolved in 0.9% saline containing 2% polygelinum (Haemaccel, Averilis Pharma, Horsholm, Denmark). The polygelinum was added to avoid adhesion of the peptide to the infusion tubes. The placebo infusion consisted of saline containing 2% polygelinum.
The infusion rate was 25 pmol/kg Â body wt Â h, which according to pilot experiments would yield concentrations GLP-2 and appetite LB Sørensen et al in plasma corresponding to high postprandial levels after large meals.
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Laboratory analyses Blood samples were drawn into test tubes, for glucose into a tube containing EDTA/fluoride, for insulin analysis a tube with no addition, and for GLP-1, GLP-2, glucose-dependent insulinotropic polypeptide (GIP), and glucagon analyses into tubes containing EDTA. The tubes (except for insulin analysis) were kept on ice during the test. The samples were centrifuged at 2800 g for 10 min at 41C, and plasma for glucose and hormone analyses were kept at -201C until use. Plasma glucose was analysed by standard enzymatic methods. 25 Insulin concentrations in plasma were measured using radio immunoassay (RIA) according to the principles of Albano et al 26 against standards of human insulin. The tracer was human insulin monoiodinated in position A14 (a gift from Novo Nordisk A/S, Bagsvoerd, DK, Denmark). The guinea pig antibody employed (code no. 2004) crossreacts with proinsulin and split insulins. The intra-assay coefficient of variation was below 5% and the sensitivity was below 5 pmol/l. GLP-1, GLP-2, GIP, and glucagon concentrations in plasma were all measured after extraction of plasma with 70% ethanol (vol/vol, final concentration). The GLP-1 was measured against standards of synthetic GLP-1 (7,3b), using antiserum code no. 89390, which is specific for the amidated C-terminus of GLP-1 of intestinal origin. 27 The C-terminally directed antiserum R 65 was used for the GIP RIA, 28 which crossreacts fully with human GIP but not with the so-called GIP 8000, whose chemical nature and relation to GIP secretion is uncertain. Human GIP and 125 I human GIP (70 MBQ/nmol) were used for standards and tracer. The glucagon RIA was directed against the C-terminus of the glucagon molecule (antibody code no. 4305) and therefore mainly measures glucagon of pancreatic origin. 29 For these three assays, sensitivity was below 1 pmol/l, intra-assay coefficient of variation below 6% at 20 pmol/l, and recovery of standard, added to plasma before extraction, about 100% when corrected for losses inherent in the plasma extraction procedure. GLP-2 concentration in ethanol-extracted plasma was measured using a RIA employing antiserum code no. 92160 and standards of human GLP-2 (proglucagon 126-158, a gift from Novo Nordisk A/S Bagsvord, DK, Denmark) and monoiodinated Tyr 12 GLP-2, specific activity o70 MBQ/nmol. 14 The antiserum is directed against the Nterminus of GLP-2 and therefore measures only fully processed GLP-2 of intestinal origin. The sensitivity was below 5 pmol/l, and the intra-assay coefficient of variation at 60 pmol/l was 6%.
Statistical analyses
The results are presented as means7s.e.m. Fasting values and energy intake were compared using a paired t-test. Postprandial response curves were evaluated by comparing postprandial mean values, peak/nadir values, time to peak/ nadir values, and the incremental AUC using a paired t-test.
To adjust for differences in energy intake, postprandial appetite ratings were compared using energy intake as a covariate. Correlation analyses were done to examine a possible association between GLP-2 concentration in the fasting period and ad libitum energy intake. Po0.05 was considered as significant. Statistical analyses were carried out with Microsoft Excel 97 and SAS software package, version 6.08 (SAS Institute, Inc., Cary, NC, USA).
Results
The GLP-2 plasma concentration was significantly higher during the infusion of GLP-2 compared to placebo (Po0.0001) and increased in both conditions in response to the test meal. The GLP-2 infusion increased concentrations from 8.971.6 pmol/l before the start of infusion to 62.173.8 pmol/l 120 min after the start of infusion and right before the test meal ( Figure 2 ). During the placebo infusion the plasma GLP-2 concentrations increased from 7.771.1 pmol/l to a peak at 27.973.5 pmol/l after the test meal ( Figure 2 ). The GLP-2 infusion did not influence the subjective feelings of hunger, satiety, fullness or prospective food consumption (Figure 3 ). Nor were there any differences in the subjective ratings of taste, smell, visual appeal, aftertaste, and overall palatability of either of the test meals on the two different test days. Furthermore, the ad libitum energy intake of the test meal was not different on the two occasions ( Figure 4 ). There was no correlation between fasting GLP-2 plasma concentrations and subsequent energy intake.
GLP-1, glucose, insulin, and GIP responses were unaffected by the GLP-2 infusion, whereas the mean postprandial concentration and nadir of glucagon were higher during 
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Discussion
This study did not confirm the hypothesis that GLP-2 is part of the ileal brake mechanism and that peripherally administered GLP-2 has an effect on appetite sensations and energy intake in humans. According to the hypothesis, the GLP-2 infusion was expected to inhibit gastric emptying and as a result reduce appetite, energy intake, and postprandial plasma concentrations of glucose, insulin, glucagon, and GIP.
In a recent study, in patients with short bowel syndrome, subcutaneous injections of 400 mg GLP-2 resulted in a delay in gastric 50% emptying of solids from 89762 to 119760 min, 30 thus suggesting that GLP-2 may act as an ileal brake. If so, what would be the mechanism of action? GLP-1 is considered an ileal brake hormone, [31] [32] [33] and a possible mechanism of action is a paracrine mechanism where GLP-1 secreted from the L-cells in the intestinal epithelium enters the lamina propria and interacts with nerve endings of sensory afferent neurons. If GLP-2 works as a paracrine transmitter as does GLP-1, the question is what GLP-2 plasma concentration is needed to gain GLP-2 concentrations in the lamina propria sufficient to activate the afferent neurons. In the study mentioned above involving patients with short bowel syndrome, injections of 400 mg GLP-2 increased plasma GLP-2 concentration to 7197281 pmol/l (range 420-1240 pmol/l). 30 In our study, the GLP-2 infusion increased plasma GLP-2 concentration from 972 to 6274 pmol/l (range 42-100 pmol/l), which is considerably lower than in the study with the short bowel patients. Endogenous GLP-2 secretion increased after mixed meal ingestion from 1572 to 6179 pmol/l in one study 14 and from 1673 to 73710 pmol/l in another study, 24 both using the same assay as in the present study. The plasma GLP-2 concentration increase in our study is therefore to be regarded as physiological. Considering this, and that there were no differences in plasma concentrations of glucose, insulin, and GIP on the two different test days support the hypothesis that GLP-2 acts as a paracrine transmitter and not as an endocrine transmitter. The increase in glucagon levels in the GLP-2 experiment was significant but very small; differences in plasma glucose GLP-2 and appetite LB Sørensen et al and insulin concentrations could not be responsible for the increase since these parameters were identical in the two experiments. It is possible but yet unproven that gut-released GLP-2 is involved in a feedback signalling mechanism on glucagon or somatostatin-producing cells in pancreas. However, conclusions on this matter must await future studies.
Peripherally infused GLP-1 promotes satiety and suppresses energy intake, but it is not known whether this is due to GLP-1's inhibitory effect on gastrointestinal motility or if it directly involves some of the brain centres regulating food intake. [8] [9] [10] A possible mechanism is that peripheral GLP-1 as a paracrine transmitter interacts with afferent pathways to the brainstem where GLP-1-producing neurons are activated. Fibres from the GLP-1-producing neurons in the brainstem project, among others, to the hypothalamus where GLP-1 is secreted and activates GLP-1 receptors. 34 Tang-Christensen et al 15 have recently confirmed that GLP-2 is produced by neurons in the brainstem and that fibres project to an area in the hypothalamus, mainly the ventromedial nucleus, where GLP-2 receptors are located. They discovered that GLP-2 administered to the lateral ventricle results in reduced energy intake in rats and the conclusion was that GLP-2 works as a neurotransmitter involved in regulating food intake. Maybe the mechanism of action of GLP-2 is the same as proposed for GLP-1, and peripheral GLP-2 has in reality an effect on appetite sensations and energy intake. The reason why our study did not show any effect of GLP-2 could be due to the low infusion rate, which resulted in a GLP-2 concentration that was not high enough to activate the afferent neurons in the lamina propria. In the present study, the VAS method was used to assess subjective appetite sensations. Flint et al 35 have studied the reproducibility, power and validity of VAS in the assessment of appetite sensations, and they concluded that using a paired design, 32 subjects are enough to achieve sufficient study power, GLP-2 and appetite LB Sørensen et al thereby minimising the risk of a type II error ('false-negative' result). If the effect parameters of interest are limited to mean appetite ratings, eight subjects are enough. Considering that the present study involved eight women and 10 men, the study might not have sufficient study power to detect an effect of GLP-2 on all parameters, yet the number of subjects would sufficiently cover a test of the mean appetite ratings even when the results were analysed according to gender. This underlines the fact that a possible effect of GLP-2 cannot be overwhelming. Thus, the lack of effect from infused GLP-2 on appetite sensations and energy intake in our study suggests that circulating GLP-2 in physiological concentrations does not play a significant role in the regulation of appetite in humans.
